Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase inhibitor (TKI) treatment for patients with chronic-phase chronic myeloid leukemia ...

Eli Lilly Canada, Inc announced today that Jaypirca® (pirtobrutinib, 100 mg & 50 mg tablets) is now approved and available ...

Scemblix showed a 68% major molecular response rate at 48 weeks, outperforming tyrosine kinase inhibitors by 19%. Common side effects included rash, musculoskeletal pain, and fatigue, with laboratory ...

By: Dr. Amrit Kaur Kaler For patients diagnosed with blood cancers such as leukemia, lymphoma, and multiple myeloma, the ...

Chronic lymphocytic leukemia (CLL) remains an incurable disease, except in rare cases treated with allogeneic stem-cell transplantation or favorable-risk CLL treated with chemoimmunotherapy. Treatment ...

ASH 2024 Acalabrutinib Combo Promising as Frontline Treatment for CLL A fixed duration combination of venetoclax with acalabrutinib, with or without obinutuzumab, was superior to standard ...

FDA Panel: Concerns Over PI3K Inhibitors in Blood Cancers An FDA advisory panel voted in favor of using randomized trials of PI3K drugs instead of single-arm studies in blood cancer studies, because ...

Personalized exercise guidance is needed for people living with Chronic Lymphocytic Leukemia (CLL), the most common type of blood cancer, according to a new study led by the University of Surrey. The ...

Chronic lymphocytic leukemia (CLL) is a type of blood cancer that affects white blood cells called lymphocytes. There are many types of leukemia, and CLL is a common type in adults. This type of ...

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic blood cancer, potential treatments for Richter transformation, and ...